<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03876119</url>
  </required_header>
  <id_info>
    <org_study_id>CHOICE</org_study_id>
    <nct_id>NCT03876119</nct_id>
  </id_info>
  <brief_title>Intraarterial Alteplase Versus Placebo After Mechanical Thrombectomy</brief_title>
  <acronym>CHOICE</acronym>
  <official_title>CHemical OptImization of Cerebral Embolectomy in Patients With Acute Stroke Treated With Mechanical Thrombectomy (CHOICE) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundació La Marató de TV3</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, randomized, placebo-controlled, double blind, phase 2b trial of acute stroke&#xD;
      patients treated with mechanical thrombectomy (MT), in which two therapies are compared:&#xD;
      rt-PA or placebo. Allocation at each center will account for 1 stratum: use of alteplase (yes&#xD;
      vs. no) before MT. Subjects will be followed up to 90 days post-randomization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objective is to evaluate whether rt-PA is safe and efficient as an add-on to&#xD;
      mechanical thrombectomy in patients with acute ischemic stroke and complete or near-complete&#xD;
      recanalization of a proximal vessel occlusion and successful brain reperfusion on cerebral&#xD;
      angiogram (corresponding to mTICI score 2b/3) The study is a multicenter, randomized,&#xD;
      placebo-controlled, double blind, phase 2b trial of acute stroke patients treated with MT, in&#xD;
      which two therapies are compared: rt-PA or placebo. Allocation at each center will account&#xD;
      for 1 stratum: use of alteplase (yes vs. no) before MT. Subjects will be followed up to 90&#xD;
      days post-randomization&#xD;
&#xD;
      Patients will be enrolled in the angiosuit by interventionalists or neurologists once a mTICI&#xD;
      2b/3 is confirmed on cerebral angiography. The primary outcome is the proportion of patients&#xD;
      with a mRS 0 to 1 at 90 days. A sample size of 100 patients per treatment arm in a 1:1&#xD;
      allocation will have at least 80% statistical power for the primary outcome (mRS with 0-1&#xD;
      score values) assuming a rate of 40% in the control arm and a 21% benefit in the experimental&#xD;
      arm (odds ratio (OR) of 2.33) for a 5% two-sided type I error. This sample size will also&#xD;
      guarantee the study power for that relative treatment benefit even if the success rate in the&#xD;
      control group rises up to ≈56%. No study losses are accounted for since all randomised&#xD;
      patients will be included in the analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, randomized, placebo-controlled, double blind, phase 2b trial of acute stroke patients treated with MT, in which two therapies are compared: rt-PA or placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The solutions of alteplase or placebo are limpid, transparent and colorless. Alteplase (Actilyse 10 mg powder and solvent for solution for injection and infusion) and placebo will be provided in kind by Boëhringer Ingelheim. The secondary conditioning of the investigation treatment will be performed by Alcura Health Spain S.A.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Good outcome at 90 days</measure>
    <time_frame>Day 90 after treatment.</time_frame>
    <description>The primary outcome will be the proportion of patients with a mRS 0 to 1 at 90 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Shift analysis of the 90-day modified Rankin Scale (mRS).</measure>
    <time_frame>Day 90 after treatment.</time_frame>
    <description>The shift analysis of the modified Rankin Scale (mRS), at day 90. The mRS at 90 days will be analyzed using a proportional odds model (POM) that combine into single worst rank the last two categories (5: severe incapacity and 6: death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct expansion ratio.</measure>
    <time_frame>48 (+/- 24h) hours of stroke</time_frame>
    <description>Infarct Expansion Ratio on DWI-MRI (continuous variable), at 48h (+/- 24h) of stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of infarct expansion at 24 hours.</measure>
    <time_frame>48 (+/- 24h) hours of stroke</time_frame>
    <description>Proportion of patients with/without infarct expansion (dichotomous variable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final infarct volume.</measure>
    <time_frame>48 (+/- 24h) hours of stroke</time_frame>
    <description>Infarction Volume on Diffusion Weighted Imaging (Magnetic Resonance Imaging) at 48h (+/- 24h) of stroke onset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic improvement on the Arterial Occlusive Lesion (AOL) scale</measure>
    <time_frame>10 minutes after treatment</time_frame>
    <description>Proportion of patients with angiographic improvement on the Arterial Occlusive Lesion (AOL) scale. AOL describes arterial patency at the site of occlusion based on the degree of luminal opening (none, partial, or complete) with further qualification based simply on the presence (grades 2 or 3) or absence (grades 0 or 1) of any downstream flow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TERTIARY OUTCOME: Barthel Scale at day 90</measure>
    <time_frame>Day 90 after treatment.</time_frame>
    <description>Barthel Scale score of 95 to 100, at day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TERTIARY OUTCOME: Ischemic worsening within 72 hours os stroke onset</measure>
    <time_frame>72 hours of stroke onset</time_frame>
    <description>Ischemic worsening (≥ 4 points in the NIHSS score) within 72 hours of stroke onset not attributable to stroke recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TERTIARY OUTCOME: Quality of life measured at 90 days</measure>
    <time_frame>Day 90 after treatment.</time_frame>
    <description>Quality of life measured with the EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D-3L) at 90 days</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of patients with improved mTICI 2b score</measure>
    <time_frame>10 minutes after treatment</time_frame>
    <description>Proportion of patients with improved mTICI 2b score&#xD;
IV Alteplase use on admission (yes versus no)&#xD;
MT started within 7.3h of symptoms onset versus MT started between 7.4h and 24h.&#xD;
Admission serum glucose concentration≤100 mg/dL versus &gt;100 mg/dL&#xD;
Males vs. Females&#xD;
Baseline angiographic score mTICI2b brain reperfusion versus baseline angiographic score eTICI2c/3 brain reperfusion.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Stroke, Acute</condition>
  <arm_group>
    <arm_group_label>Intraarterial alteplase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All the patients will be given a 15 minutes IA infusion of alteplase (Actylise®) at a drug concentration of 1.0 mg/ml. At 15 minutes of IA treatment onset, the infusion will be stopped and the angiographic score assessed. If the angiographic score is improved compared with the baseline score the procedure is terminated, otherwise a new angiographic series will be repeated in 10 minutes before the end of the procedure in front and profile projections.&#xD;
Study drug will be prepared according to the following steps:&#xD;
Dilute 3 vials of 10 mgs (alteplase) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml&#xD;
Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo will consist of a lyophilized white powder containing 0.2 mol/L arginine phosphate, 0.01% polysorbate 80, and pH 7.4 after reconstitution.&#xD;
Study drug will be prepared according to the following steps:&#xD;
Dilute 3 vials of 10 mgs (placebo) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml&#xD;
Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intraarterial alteplase</intervention_name>
    <description>See arm/group descriptions.</description>
    <arm_group_label>Intraarterial alteplase</arm_group_label>
    <other_name>Intraarterial alteplase recombinant tissue plasminogen activator (rTPA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>See arm/group descriptions.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          1. Patients with symptomatic large vessel occlusion (LVO) in the anterior, middle or&#xD;
             posterior cerebral artery treated with MT resulting in an mTICI score 2b/3 at end of&#xD;
             the procedure.. Patients with an mTICI score 2b/3 on the diagnostic cerebral&#xD;
             angiography before the onset of MT are also eligible for the study.&#xD;
&#xD;
          2. Estimated delay to onset of rescue intraarterial rt-PA administration &lt;24 hours from&#xD;
             symptom onset, defined as the point in time the patient was last seen well&#xD;
&#xD;
          3. No significant pre-stroke functional disability (modified Rankin scale 0-1), or mRS &gt;1&#xD;
             that according to the investigator is not related to neurological disease (i.e.&#xD;
             amputation, blindness)&#xD;
&#xD;
          4. Age ≥18&#xD;
&#xD;
          5. ASPECTS &gt;6 on non-contrast CT (NCCT) scan or MRI if symptoms lasting &lt;4.5 hours or&#xD;
             ASPECTS &gt;6 on CT-Perfusion (CTP) or DWI-MRI if symptoms &gt;4.5 &lt;24 hours.&#xD;
&#xD;
          6. Informed consent obtained from patient or acceptable patient surrogate&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. NIHSS score on admission &gt;25&#xD;
&#xD;
          2. Contraindication to IV t-PA as per local national guidelines (except time to therapy)&#xD;
&#xD;
          3. Use of carotid artery stents during the endovascular procedure requiring dual&#xD;
             antiplatelet therapy during the first 24h&#xD;
&#xD;
          4. Female who is pregnant or lactating or has a positive pregnancy test at time of&#xD;
             admission&#xD;
&#xD;
          5. Current participation in another investigation drug or device treatment study (except&#xD;
             observational study i.e.: RACECAT or clinical trials not testing new medical devices&#xD;
             or new drugs i.e.IMAGECAT)&#xD;
&#xD;
          6. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency&#xD;
&#xD;
          7. Known coagulopathy, INR &gt; 1.7 or use of novel anticoagulants &lt; 48h from symptom onset&#xD;
&#xD;
          8. Platelets &lt; 50,000&#xD;
&#xD;
          9. Renal Failure as defined by a serum creatinine &gt; 3.0 mg/dl (or 265.2 μmol/l) or&#xD;
             glomerular Filtration Rate [GFR] &lt; 30&#xD;
&#xD;
         10. Subject who requires hemodialysis or peritoneal dialysis, or who have a&#xD;
             contraindication to an angiogram for whatever reason&#xD;
&#xD;
         11. Any hemorrhage on CT/MRI&#xD;
&#xD;
         12. Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT or MRI&#xD;
             scan is normal&#xD;
&#xD;
         13. Suspicion of aortic dissection&#xD;
&#xD;
         14. Subject currently uses or has a recent history of illicit drug(s) or abuses alcohol&#xD;
&#xD;
         15. History of life threatening allergy (more than rash) to contrast medium&#xD;
&#xD;
         16. SBP &gt;185 mmHg or DBP &gt;110 mmHg refractory to treatment&#xD;
&#xD;
         17. Serious, advanced, terminal illness with anticipated life expectancy &lt; 6 months&#xD;
&#xD;
         18. Pre-existing neurological or psychiatric disease that would confound evaluation&#xD;
&#xD;
         19. Presumed vasculitis or septic embolization&#xD;
&#xD;
         20. Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor&#xD;
             from overseas)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angel Chamorro, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Comprehensive Stroke Center, Hospital Clinic Barcelona.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arturo Renú, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comprehensive Stroke Center, Hospital Clinic Barcelona.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marián Muchada, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Vall d'Hebrón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elisa Cuadrado, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital del Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Ramos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pol Camps, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pere Cardona, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mikel Terceño, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Josep Trueta Girona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martha Vargas, PhD</last_name>
    <phone>0034-93 227 54 00</phone>
    <phone_ext>2118</phone_ext>
    <email>mvargas@clinic.ub.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sergi Amaro, MD, PhD</last_name>
    <phone>0034-93 227 54 00</phone>
    <phone_ext>2118</phone_ext>
    <email>samaro@clinic.ub.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Germans Trias i Pujol Hospital</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Ramos, MD</last_name>
      <email>annaramosp@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arturo Renú, MD, PhD</last_name>
      <phone>932275414</phone>
      <email>arenu@clinic.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Cuadrado, MD</last_name>
      <email>elisacua@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan M Fábregas, MD,PhD</last_name>
      <email>jmarti@santpau.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pere Cardona, MD,PhD</last_name>
      <email>pcardonap@bellvitgehospital.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marian Muchada, MD,PhD</last_name>
      <email>muchadamarian@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Josep Trueta (HJT)</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikel Terceño, MD</last_name>
      <email>mikelterceno@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Chamorro Á, Blasco J, López A, Amaro S, Román LS, Llull L, Renú A, Rudilosso S, Laredo C, Obach V, Urra X, Planas AM, Leira EC, Macho J. Complete reperfusion is required for maximal benefits of mechanical thrombectomy in stroke patients. Sci Rep. 2017 Sep 14;7(1):11636. doi: 10.1038/s41598-017-11946-y.</citation>
    <PMID>28912596</PMID>
  </reference>
  <reference>
    <citation>Dávalos A, Cobo E, Molina CA, Chamorro A, de Miquel MA, Román LS, Serena J, López-Cancio E, Ribó M, Millán M, Urra X, Cardona P, Tomasello A, Castaño C, Blasco J, Aja L, Rubiera M, Gomis M, Renú A, Lara B, Martí-Fàbregas J, Jankowitz B, Cerdà N, Jovin TG; REVASCAT Trial Investigators. Safety and efficacy of thrombectomy in acute ischaemic stroke (REVASCAT): 1-year follow-up of a randomised open-label trial. Lancet Neurol. 2017 May;16(5):369-376. doi: 10.1016/S1474-4422(17)30047-9. Epub 2017 Mar 16.</citation>
    <PMID>28318984</PMID>
  </reference>
  <reference>
    <citation>Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, San Román L, Serena J, Abilleira S, Ribó M, Millán M, Urra X, Cardona P, López-Cancio E, Tomasello A, Castaño C, Blasco J, Aja L, Dorado L, Quesada H, Rubiera M, Hernandez-Pérez M, Goyal M, Demchuk AM, von Kummer R, Gallofré M, Dávalos A; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015 Jun 11;372(24):2296-306. doi: 10.1056/NEJMoa1503780. Epub 2015 Apr 17.</citation>
    <PMID>25882510</PMID>
  </reference>
  <reference>
    <citation>Renú A, Blasco J, Millán M, Martí-Fàbregas J, Cardona P, Oleaga L, Macho J, Molina C, Roquer J, Amaro S, Dávalos A, Zarco F, Laredo C, Tomasello A, Guimaraens L, Barranco R, Castaño C, Vivas E, Ramos A, López-Rueda A, Urra X, Muchada M, Cuadrado-Godía E, Camps-Renom P, Román LS, Ríos J, Leira EC, Jovin T, Torres F, Chamorro Á; CHOICE Investigators. The Chemical Optimization of Cerebral Embolectomy trial: Study protocol. Int J Stroke. 2021 Jan;16(1):110-116. doi: 10.1177/1747493019895656. Epub 2019 Dec 18.</citation>
    <PMID>31852410</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Angel Chamorro, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Director, Comprehensive Stroke Center, Hospital Clinic Barcelona. Professor of Neurology, University of Barcelona.</investigator_title>
  </responsible_party>
  <keyword>Mechanical Thrombectomy</keyword>
  <keyword>Recanalization</keyword>
  <keyword>Reperfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Plasminogen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified individual participant data on outcome measures will be published along with the main results of the trial.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The data will become available after publication of main study results.</ipd_time_frame>
    <ipd_access_criteria>The IPD will be available from the Sponsor of the trial on reasonable request.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT03876119/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

